| 47.55 0.03 (0.06%) | 08-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 45.03 | 1-year : | 55.86 |
| Resists | First : | 38.55 | Second : | 47.83 |
| Pivot price | 24.82  |
|||
| Supports | First : | 23.54 | Second : | 19.59 |
| MAs | MA(5) : | 24.1  |
MA(20) : | 24.75 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 15.1 |
| RSI | RSI(14): 20.1 |
|||
| 52-week | High : | 26.15 | Low : | 23.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DICE ] has closed above bottom band by 31.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 24.29 - 24.44 | 24.44 - 24.58 |
| Low: | 23.57 - 23.74 | 23.74 - 23.91 |
| Close: | 24.01 - 24.27 | 24.27 - 24.52 |
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.
Wed, 14 Oct 2026
Old Fitzgerald Bourbon and Jonathan Adler Roll the Dice on New Limited-Edition Backgammon Set - Yahoo Finance
Fri, 09 Oct 2026
Dice Therapeutics, Inc. (DICE) Stock Price, News, Earnings & Company Profile - RTTNews
Thu, 24 Sep 2026
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Wed, 09 Sep 2026
Tema Launches Trading & Prediction Markets ETF (DICE) - Yahoo Finance
Tue, 20 Jun 2023
Lilly to Acquire DICE Therapeutics for $2.4B - Contract Pharma
Tue, 20 Jun 2023
Lilly to buy oral immune drug developer Dice Therapeutics for $2.4B - BioPharma Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|